Semzuvolimab |
dB4; UB-421; mAb-B4 |
Phase 3 Clinical |
United Biomedical Inc |
HIV Infections |
Details
|
ITV 1(Nonindustrial source) |
ITV-1 |
Phase 3 Clinical |
Synexa Life Sciences, Immunotech Laboratories |
HIV Infections |
Details
|
RB-0003 |
RB-0003; BNT-111 |
Phase 2 Clinical |
Biontech Se, Tron |
Melanoma |
Details
|
VRC-01-LS |
VRC-HIVMAB-080-00-AB; VRC-01-LS |
Phase 2 Clinical |
National Institute Of Allergy And Infectious Diseases (Niaid) |
HIV Infections |
Details
|
VRC-07-523 |
VRC-07-523-L S; VRC-HIVMAB075-00-AB; VRC-HIVMAB-075 -00-AB; VRC-07-523; TMB-380 |
Phase 2 Clinical |
National Institute Of Allergy And Infectious Diseases (Niaid), Taimed Biologics Inc |
Acquired Immunodeficiency Syndrome; HIV Infections; Retroviridae Infections; Sexually Transmitted Diseases, Viral; HIV Seropositivity |
Details
|
GEN-009 |
GEN-009 |
Phase 2 Clinical |
Genocea Biosciences Inc |
Skin Melanoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung |
Details
|
Tregalizumab |
hB-F5; BT-061 |
Phase 2 Clinical |
Biotest Pharma Gmbh |
Drug Hypersensitivity; Arthritis, Rheumatoid; Psoriasis; Asthma |
Details
|
MVA-EL |
MVA-EBNA1/LMP2 |
Phase 2 Clinical |
Chinese University Of Hong Kong (Cuhk), Cancer Research UK |
Head and Neck Neoplasms; Stomach Neoplasms; Nasopharyngeal Neoplasms; Lymphoproliferative Disorders; Epstein-Barr Virus Infections; Lymphoma |
Details
|
VRC-HIVMAB091-00-AB |
N6LS; Z258‐N6LS; VRC-HIVMAB091-00-AB |
Phase 2 Clinical |
National Institute Of Allergy And Infectious Diseases (Niaid) |
HIV Infections |
Details
|
IMCY-0141 |
IMCY-0141 |
Phase 2 Clinical |
Imcyse Sa |
Multiple Sclerosis, Relapsing-Remitting |
Details
|
Autologous Regulatory Т-cell Therapy |
|
Phase 2 Clinical |
Institute Of Biophysics And Cell Engineering Of National Academy Of Sciences Of Belarus |
Scleroderma, Systemic |
Details
|
CD4-directed chimeric antigen receptor engineered T-cells (Icell Gene) |
CD4CAR (Icell Gene) |
Phase 1 Clinical |
Stony Brook University School Of Medicine, Icell Gene Therapeutics (Int'L) Ltd, University Of Louisville |
Leukemia, Myelomonocytic, Chronic; Lymphoma, T-Cell; Leukemia, T-Cell |
Details
|
T-allo-10 |
T-allo-10 |
Phase 1 Clinical |
Stanford University |
Hematologic Diseases; Leukemia; Graft vs Host Disease; Hodgkin Disease; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin |
Details
|
Anti-CD4 CAR T-cell therapy (University of Pennsylvania) |
CAR-C34ZFN |
Phase 1 Clinical |
University Of Pennsylvania |
HIV Infections; HIV Seropositivity |
Details
|
10E8.4/iMab (Aaron Diamond AIDS Research Center) |
TMB-370 |
Phase 1 Clinical |
Aaron Diamond Aids Research Center For The City Of New York, Inc |
HIV Infections |
Details
|
CALRLong36 peptide (Herlev Hospital) |
|
Phase 1 Clinical |
Herlev Hospital |
Myeloproliferative Disorders |
Details
|
VRC-HIVMAB060-00-AB |
VRC-HIVMAB060-00-AB; VRC01 |
Phase 1 Clinical |
National Institute Of Allergy And Infectious Diseases (Niaid) |
HIV Infections |
Details
|
VRC-HIVMAB0115-00-AB |
|
Phase 1 Clinical |
National Institute Of Allergy And Infectious Diseases (Niaid) |
HIV Infections; HIV Seropositivity |
Details
|
SCRI-E2CAR_EGFRtv1 |
SCRI-E2CAR_EGFRtv1 |
Phase 1 Clinical |
Umoja BioPharma Inc |
Osteosarcoma |
Details
|
CD4^LVFOXP3 Treg-like cell therapy |
CD4^LVFOXP3 |
Phase 1 Clinical |
Stanford University |
Polyendocrinopathies, Autoimmune |
Details
|
TMB-365 |
TMB-365 |
Phase 1 Clinical |
Taimed Biologics Inc |
HIV Infections |
Details
|
LB-1901 |
LB1901; LB-1901 |
Phase 1 Clinical |
|
Lymphoma, T-Cell, Peripheral; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous |
Details
|
IT-1208 (Kyowa Hakko Kirin) |
IT-1208 |
Phase 1 Clinical |
Kyowa Hakko Kirin Co Ltd |
Neoplasms |
Details
|
Semzuvolimab |
dB4; UB-421; mAb-B4 |
Phase 3 Clinical |
United Biomedical Inc |
HIV Infections |
Details
|
ITV 1(Nonindustrial source) |
ITV-1 |
Phase 3 Clinical |
Synexa Life Sciences, Immunotech Laboratories |
HIV Infections |
Details
|
RB-0003 |
RB-0003; BNT-111 |
Phase 2 Clinical |
Biontech Se, Tron |
Melanoma |
Details
|
VRC-01-LS |
VRC-HIVMAB-080-00-AB; VRC-01-LS |
Phase 2 Clinical |
National Institute Of Allergy And Infectious Diseases (Niaid) |
HIV Infections |
Details
|
VRC-07-523 |
VRC-07-523-L S; VRC-HIVMAB075-00-AB; VRC-HIVMAB-075 -00-AB; VRC-07-523; TMB-380 |
Phase 2 Clinical |
National Institute Of Allergy And Infectious Diseases (Niaid), Taimed Biologics Inc |
Acquired Immunodeficiency Syndrome; HIV Infections; Retroviridae Infections; Sexually Transmitted Diseases, Viral; HIV Seropositivity |
Details
|
GEN-009 |
GEN-009 |
Phase 2 Clinical |
Genocea Biosciences Inc |
Skin Melanoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung |
Details
|
Tregalizumab |
hB-F5; BT-061 |
Phase 2 Clinical |
Biotest Pharma Gmbh |
Drug Hypersensitivity; Arthritis, Rheumatoid; Psoriasis; Asthma |
Details
|
MVA-EL |
MVA-EBNA1/LMP2 |
Phase 2 Clinical |
Chinese University Of Hong Kong (Cuhk), Cancer Research UK |
Head and Neck Neoplasms; Stomach Neoplasms; Nasopharyngeal Neoplasms; Lymphoproliferative Disorders; Epstein-Barr Virus Infections; Lymphoma |
Details
|
VRC-HIVMAB091-00-AB |
N6LS; Z258‐N6LS; VRC-HIVMAB091-00-AB |
Phase 2 Clinical |
National Institute Of Allergy And Infectious Diseases (Niaid) |
HIV Infections |
Details
|
IMCY-0141 |
IMCY-0141 |
Phase 2 Clinical |
Imcyse Sa |
Multiple Sclerosis, Relapsing-Remitting |
Details
|
Autologous Regulatory Т-cell Therapy |
|
Phase 2 Clinical |
Institute Of Biophysics And Cell Engineering Of National Academy Of Sciences Of Belarus |
Scleroderma, Systemic |
Details
|
CD4-directed chimeric antigen receptor engineered T-cells (Icell Gene) |
CD4CAR (Icell Gene) |
Phase 1 Clinical |
Stony Brook University School Of Medicine, Icell Gene Therapeutics (Int'L) Ltd, University Of Louisville |
Leukemia, Myelomonocytic, Chronic; Lymphoma, T-Cell; Leukemia, T-Cell |
Details
|
T-allo-10 |
T-allo-10 |
Phase 1 Clinical |
Stanford University |
Hematologic Diseases; Leukemia; Graft vs Host Disease; Hodgkin Disease; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin |
Details
|
Anti-CD4 CAR T-cell therapy (University of Pennsylvania) |
CAR-C34ZFN |
Phase 1 Clinical |
University Of Pennsylvania |
HIV Infections; HIV Seropositivity |
Details
|
10E8.4/iMab (Aaron Diamond AIDS Research Center) |
TMB-370 |
Phase 1 Clinical |
Aaron Diamond Aids Research Center For The City Of New York, Inc |
HIV Infections |
Details
|
CALRLong36 peptide (Herlev Hospital) |
|
Phase 1 Clinical |
Herlev Hospital |
Myeloproliferative Disorders |
Details
|
VRC-HIVMAB060-00-AB |
VRC-HIVMAB060-00-AB; VRC01 |
Phase 1 Clinical |
National Institute Of Allergy And Infectious Diseases (Niaid) |
HIV Infections |
Details
|
VRC-HIVMAB0115-00-AB |
|
Phase 1 Clinical |
National Institute Of Allergy And Infectious Diseases (Niaid) |
HIV Infections; HIV Seropositivity |
Details
|
SCRI-E2CAR_EGFRtv1 |
SCRI-E2CAR_EGFRtv1 |
Phase 1 Clinical |
Umoja BioPharma Inc |
Osteosarcoma |
Details
|
CD4^LVFOXP3 Treg-like cell therapy |
CD4^LVFOXP3 |
Phase 1 Clinical |
Stanford University |
Polyendocrinopathies, Autoimmune |
Details
|
TMB-365 |
TMB-365 |
Phase 1 Clinical |
Taimed Biologics Inc |
HIV Infections |
Details
|
LB-1901 |
LB1901; LB-1901 |
Phase 1 Clinical |
|
Lymphoma, T-Cell, Peripheral; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous |
Details
|
IT-1208 (Kyowa Hakko Kirin) |
IT-1208 |
Phase 1 Clinical |
Kyowa Hakko Kirin Co Ltd |
Neoplasms |
Details
|